BACKGROUND: Breast cancer is a heterogeneous disease with well-known characteristics such as hormone receptor (HR) status and human epidermal growth factor (Her)2 status. Although Her2 represents an established treatment target, the development of resistance mechanisms during treatment, cardiotoxicity, and a worse response to standard therapies lead to worse outcomes. SUMMARY: Therefore, we investigated various biomarkers in breast cancer such as Her2 mutations, Her2 heterogeneity, HR, PIK3CA, PTEN, programmed death receptor ligand 1 (PD-L1), tumor-infiltrating lymphocytes (TIL), micro RNA (miRNA), and BRCA mutations with regard to their clinical impact in Her2-positive disease. HR status and Her2 status, such as the presence of PIK3CA mutations, already play a role in treatment decision-making processes, whereas other biomarkers like PD-L1 status or TIL represent promising future markers. The influence of BRCA mutations in Her2-positive disease, Her2 mutations, and the impact of miRNA is vague to date. Antibody-drug conjugates (ADC) such as T-DM have been established as important treatment strategies, especially in Her2-positive disease. KEY MESSAGE: However, up-to-date biomarkers appropriate for clinical practice are missing. Further studies are needed.
BACKGROUND: Breast cancer is a heterogeneous disease with well-known characteristics such as hormone receptor (HR) status and human epidermal growth factor (Her)2 status. Although Her2 represents an established treatment target, the development of resistance mechanisms during treatment, cardiotoxicity, and a worse response to standard therapies lead to worse outcomes. SUMMARY: Therefore, we investigated various biomarkers in breast cancer such as Her2 mutations, Her2 heterogeneity, HR, PIK3CA, PTEN, programmed death receptor ligand 1 (PD-L1), tumor-infiltrating lymphocytes (TIL), micro RNA (miRNA), and BRCA mutations with regard to their clinical impact in Her2-positive disease. HR status and Her2 status, such as the presence of PIK3CA mutations, already play a role in treatment decision-making processes, whereas other biomarkers like PD-L1 status or TIL represent promising future markers. The influence of BRCA mutations in Her2-positive disease, Her2 mutations, and the impact of miRNA is vague to date. Antibody-drug conjugates (ADC) such as T-DM have been established as important treatment strategies, especially in Her2-positive disease. KEY MESSAGE: However, up-to-date biomarkers appropriate for clinical practice are missing. Further studies are needed.
Authors: Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu Journal: Science Date: 2004-03-11 Impact factor: 47.728
Authors: Sara M Tolaney; Andrew M Wardley; Stefania Zambelli; John F Hilton; Tiffany A Troso-Sandoval; Francesco Ricci; Seock-Ah Im; Sung-Bae Kim; Stephen Rd Johnston; Arlene Chan; Shom Goel; Kristen Catron; Sonya C Chapman; Gregory L Price; Zhengyu Yang; M Corona Gainford; Fabrice André Journal: Lancet Oncol Date: 2020-04-27 Impact factor: 41.316
Authors: Sherene Loi; Anita Giobbie-Hurder; Andrea Gombos; Thomas Bachelot; Rina Hui; Giuseppe Curigliano; Mario Campone; Laura Biganzoli; Hervé Bonnefoi; Guy Jerusalem; Rupert Bartsch; Manuela Rabaglio-Poretti; Roswitha Kammler; Rudolf Maibach; Mark J Smyth; Angelo Di Leo; Marco Colleoni; Giuseppe Viale; Meredith M Regan; Fabrice André Journal: Lancet Oncol Date: 2019-02-11 Impact factor: 41.316
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: S Gori; A Sidoni; M Colozza; I Ferri; M G Mameli; D Fenocchio; L Stocchi; J Foglietta; V Ludovini; E Minenza; V De Angelis; L Crinò Journal: Ann Oncol Date: 2009-02-02 Impact factor: 32.976
Authors: Thomas Holbro; Roger R Beerli; Francisca Maurer; Magdalena Koziczak; Carlos F Barbas; Nancy E Hynes Journal: Proc Natl Acad Sci U S A Date: 2003-07-09 Impact factor: 11.205